LITMUS Molecular Design
LITMUS Molecular Design (LMD) creates and characterizes molecular entities.
LMD is a subsidiary of LITMUS, LLC using a proprietary technology (LITMUS Spectral ModelingTM) to accurately predict a molecule's:
-
Chemical reactivity
-
Biological activity
-
Receptor binding affinity
-
Toxicity, carcinogenicity
-
Metabolism
-
Absorption/through-membrane transmission,
-
and chemical and physical properties,
… based upon spectral information versus structural characteristics as with most drug discovery methods.
Using this approach, LMD has designed three groups of compounds available for out licensing for development:
-
Antipsychotics
-
HSP-90 cancer therapy
-
Orexin 1